Group A * (n = 87) | Group B^ (n = 194) | p-value | |
---|---|---|---|
Median age (range) | 67 (34–92) | 70 (32–94) | 0.25 |
Gender | 0.348 | ||
Male (%) | 61 (70.1%) | 124 (63.9%) | |
Female (%) | 26 (29.9%) | 70 (36.1%) | |
Tumor site, n (%) | 0.838 | ||
Caecum | 4 (4.6%) | 13 (6.7%) | |
Ascending | 5 (5.7%) | 21 (10.8) | |
Hepatic Flexure | 6 (6.9%) | 6 (3.1%) | |
Transverse | 2 (2.3%) | 5 (2.6%) | |
Splenic Flexure | 1 (1.2%) | 3 (1.5%) | |
Descending | 4 (4.6%) | 9 (4.6%) | |
Sigmoid | 27 (31.0%) | 47 (24.2%) | |
Rectum | 38 (43.7%) | 90 (46.9%) | |
T Stage, n (%) | 0.434 | ||
T1 | 17 (19.5%) | 21 (10.8%) | |
T2 | 15 (17.2%) | 37 (19.1%) | |
T3 | 43 (49.4%) | 115 (59.3%) | |
T4 | 12 (13.8%) | 21 (10.8%) | |
N Stage, n (%) | 0.361 | ||
N0 | 50 (57.5%) | 102 (52.6%) | |
N1 | 21 (24.1%) | 44 (22.7%) | |
N2 | 16 (18.4%) | 48 (24.7%) | |
Lympho-vascular Invasion, n (%) | 25 (28.7%) | 60 (30.9%) | 0.688 |
Peri-neural invasion, n(%) | 17 (19.5%) | 33 (17.0%) | 0.625 |